AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage China’s scientific expertise, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver treatments to patients across China and globally.

Pascal Soriot, CEO, AstraZeneca, said: “Today’s landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing, and global public health. By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China’s high-quality development and, most importantly, bring next-generation modalities to patients.”

The investment, announced during the UK Prime Minister’s visit to China, will significantly enhance AstraZeneca’s cell therapy and radioconjugates capabilities to help patients with cancer, haematological conditions and autoimmune diseases, among others. These investments span the value chain, from drug discovery and clinical development to manufacturing, and bring Chinese innovation to the world through partnerships with leading biotechs including AbelZeta, CSPC, Harbour BioMed, Jacobio and Syneron Bio. Building on the 2024 acquisition of Gracell Biotechnologies, AstraZeneca will also become the first global biopharmaceutical leader with end-to-end cell therapy capabilities in China.

These investments build on AstraZeneca’s R&D footprint, including global strategic R&D centers in Beijing and Shanghai, which collaborate with over 500 clinical hospitals, and have led on a large number of global clinical trials in the past three years alone. The company will also develop its existing manufacturing facilities in Wuxi, Taizhou, Qingdao, and Beijing, which provide high-quality medicines to patients in China and 70 markets worldwide, together with the establishment of new sites to be announced. Together, these investments will grow the company’s highly skilled workforce in China beyond 20,000 and create thousands of additional jobs across the healthcare ecosystem.

More AstraZeneca News

Last year, AstraZeneca announced a $50 billion investment in the United States by 2030.